Icure Pharmaceutical In

At a glance

Icure Pharmaceutical In filed 90 disclosures in the last 12 months, including 6 insider, 3 5% holder and 1 issuance. The most recent key filing was on Oct 7.

Revenue for 2025 was ₩83.4B, up 64.9% on 2024. It made an operating loss of ₩12B. Debt was 270% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩69.8B and operating profit of ₩2.6B.

The 2025 annual report lists 286 employees with an average tenure of 2.7 years and average pay of ₩10.7M, #1829 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩123.5M each on average. It paid no cash dividend for 2025. 최영권 and related parties held 15.08% at year end.

From the 2025 annual report

Staff: 286 (126 men, 160 women), of whom 46 on fixed-term contracts. Total pay for the year: ₩3B. Directors and auditors: 6, paid ₩740.8M in total.

No cash dividend was paid for 2025.

Largest shareholder

최영권 holds 13.60%; with 5 related parties the group holds 15.08% of common shares at year end.

Individuals paid ₩500M or more

Auditor: 선일회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary